However, since 2022, the new WHO classification has added more genetic mutations that classify diffuse astrocytoma as grade IV gliomas (homozygous CDKN2A/B deletion, TERT promoter mutation, EGFR gene amplification, and chromosome 7 gain/chromosome 10 loss). Here, CDKN2A is linked to diffuse astrocytoma.